10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG Net Income

Bottom-line profit, the starting point for calculating cash from operations.

10x Genomics, Inc.NASDAQ: TXG

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income turns negative

Q2 FY2026 net income was -$17.93M, compared with $34.54M a year earlier. Trailing-twelve-month net income was -$75.13M. Over 3 fiscal years it compounded at -36.0% a year.

Context

  • Net income amounted to 6.8% of revenue in FY2025, down 23.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 11 analysts of -$79.83M (+83.3%) for the fiscal year ending Dec 2026, a step up from the -76.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$17.93M+33.1% QoQ
Last fiscal yearDec 2025
-$43.54M-76.2% YoY
LTMJun 2026
-$75.13M-11.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-151.9%+27.1%+179.0 pp
1 year-76.2%+83.3%+159.5 pp
3-year CAGR-36.0%+6.8%+42.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(43.54M) USD
Year-over-year change
+76.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's LTM Jun 2026 net income of $75.13M is the smallest of the 9 companies compared; the peer median is $205.59M.
  • Its year-over-year change of -11.2% is the 7th highest of 9, against a peer median of +27.4%.
  • Net income amounts to 12.2% of revenue for TXG, versus a peer median of 16.7%.
TXG Competitors Peer median
Net Income for TXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$1.44B +18.0%-29.8%19.5%
ILMNIllumina, Inc.LTM Jun 2026$484M -45.7%—10.8%
QGENQiagen N.V.LTM Jun 2026$409.32M +9.6%+0.1%19.5%
RVTYRevvity, Inc.LTM Jul 2026$239.22M -14.2%-22.2%8.2%
TECHBio-Techne CorporationLTM Sep 2026$171.97M +120.5%-14.0%14.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$162.3M +36.7%—6.3%
TWSTTwist Bioscience CorporationLTM Sep 2026$130.2M +67.6%-14.0%28.3%
LABStandard BioTools Inc.LTM Mar 2026$78.21M +158.9%-26.7%90.7%
TXG10x Genomics, Inc.LTM Jun 2026$75.13M -11.2%-36.0%12.2%
Peer median (excluding TXG) $205.59M+27.4%-18.1%16.7%

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.22M)(166M)(255.1M)(182.63M)(43.54M)
Depreciation & Amortization28.25M33.01M43.62M43.71M43.82M
Deferred Income Tax00000
Stock-Based Compensation95.96M136.85M166.95M140.75M109.12M
Change in Working Capital(87.45M)(39.42M)17.34M1.25M24.94M
Accounts Receivables(34.04M)(18.95M)(10.61M)26.95M6.44M
Inventory(30.13M)(21.19M)7.87M(9.78M)27.95M
Accounts Payables11.08M5.86M(6.02M)(3.35M)(2.13M)
Other Working Capital(34.36M)(5.14M)26.1M(12.57M)(7.33M)
Other Non-Cash Items79K1.96M11.99M3.58M1.72M
Operating Cash Flow(21.37M)(33.61M)(15.2M)6.66M136.05M
Capital Expenditures(101.28M)(131.66M)(49.52M)(12.39M)(5.94M)
Acquisitions (Net)(5.45M)(4M)00(9.27M)
Purchases of Investments0(282.87M)0(48.88M)(123.44M)
Sales of Investments067.65M183.02M29.64M125.2M
Other Investing Activities00(923K)(1M)0
Investing Cash Flow(106.73M)(350.89M)133.49M(32.63M)(13.44M)
Debt Repayment(5.03M)(5.41M)(5.81M)00
Common Stock Issued40.33M21.23M19.48M10.91M6.8M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow35.3M15.82M13.67M10.91M6.8M
Effect of Forex Changes234K(44K)(33K)(164K)484K
Net Change in Cash(92.57M)(368.72M)131.93M(15.22M)129.9M
Free Cash Flow(122.65M)(165.27M)(64.72M)(5.73M)130.12M

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.